<DOC>
	<DOCNO>NCT01489020</DOCNO>
	<brief_summary>Based EMA ( European Medicines Agency ) new guideline clinical development product immunotherapy treatment allergic disease aim study ass safety tolerability 3 different subcutaneous immunotherapy dose escalation patient allergic Dermatophagoides pteronyssinus .</brief_summary>
	<brief_title>Subcutaneous Immunotherapy Patients Sensitized Dermatophagoides Pteronyssinus ( DPT )</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<criteria>1 . Patients allergic rhinoconjunctivitis without asthma DPT minimum 1 year prior study participation . 2 . Patients must sign informed consent form . 3 . Patients must 18 60 year age . 4 . Patients obtain prick test result great equal 3 mm diameter specific IgE great equal class 2 ( CAP/PHADIA ) DPT . 5 . Patients preferably monosensitized DPT . In case polysensitized patient include sensitization cause seasonal allergen whose pollination overlap study period . 6 . Women childbearing potential must negative urine pregnancy test Screening visit/Visit 0 7 . Women childbearing potential must agree use appropriate contraception method study sexually active 1 . Stable continued use medication allergic pathology 2 week prior inclusion . 2 . Patients sensitise perennial allergen clinically relevant specific IgE level great equal class 2 CAP/PHADIA . 3 . Patients receive immunotherapy previous 5 year DPT allergen cross reactivity patient currently receive immunotherapy allergen . 4 . Patients severe asthma FEV1 minor 70 % asthma require inhale systemic corticoid treatment time study entry within 8 week prior treatment initiation . 5 . Patients : immunological , cardiac , renal hepatic illness medical condition investigator deem relevant interfere study . 6 . Patients previous history anaphylaxis 7 . Patients chronic urticaria 8 . Patients unstable angina 9 . Patients uncontrolled hypertension 10 . Patients clinically significant arrythmias 11 . Patients neoplasia 12 . Patients clinically relevant malformation upper respiratory tract . 13 . Other chronic immunological disease could interfere assessment investigational product could generate additional risk patient 14 . Patients participate another clinical trial within 3 month prior enrolment . 15 . Patients treatment tricyclic antidepressives , psychotropics betablockers , Angiotensin Converting Enzyme Inhibitors ( ACEI ) 16 . Female patient pregnant breastfeed woman childbearing potential agree use appropriate contraception method study sexually active , surgically sterilise present incapacity bear 17 . Patient attend visit 18 . Patient 's lack collaboration refusal participate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Allergy</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Allergic Rhinoconjunctivitis</keyword>
	<keyword>D. pteronyssinus</keyword>
	<keyword>house dust allergy</keyword>
</DOC>